CHS vs. Cyclic Vomiting in Columbus, GA: Key Differences

Understand overlap between cannabis-related hyperemesis and cyclic vomiting, how research definitions differ, and why symptoms cannot diagnose an individual.

Two adults having a quiet conversation across a table.

Recurring vomiting can be frightening, especially when cannabis use adds another question about the cause. Cannabinoid hyperemesis syndrome (CHS) and cyclic vomiting syndrome (CVS) can overlap in how they appear. The important differences involve more than recognizing nausea, vomiting, or abdominal pain. They also involve the sequence of symptoms and cannabis exposure, how researchers selected participants, and whether a study counted examined patients or coded emergency department visits. For adults and loved ones in Columbus, GA, those distinctions can help explain why medical assessment remains necessary.

Why CHS and cyclic vomiting can look alike

CHS and CVS can involve recurring vomiting, so symptoms alone do not reliably explain the cause. This distinction matters when connecting medical concerns with an individualized addiction treatment plan: whole-person planning recognizes health needs without assuming every symptom comes from substance use. River City Recovery’s outpatient addiction treatment in Columbus, GA is a separate consideration from identifying the cause of vomiting.

Cyclic vomiting describes a recurring symptom pattern. CVS is a clinical syndrome label, while CHS concerns cyclic vomiting associated with chronic cannabis exposure. The overlap does not make the terms interchangeable. A person’s cannabis history may be relevant, but its presence does not automatically explain the vomiting. Likewise, a cyclic-vomiting label does not, by itself, establish whether cannabis contributed.

The authors of a prospective emergency department study of suspected CHS explicitly described the difficulty of distinguishing CHS from CVS in people with chronic cannabis use during an emergency visit. Their participants were recruited while symptomatic and still using cannabis. That setting limited what could be established at enrollment, which is why the term “suspected” matters when interpreting their findings.

The two studies were not a head-to-head diagnostic trial that established a reliable symptom-based way to separate CHS from CVS. One examined a selected group of adults with suspected CHS. The other examined national patterns in emergency department diagnosis codes. They answer useful but different questions, rather than supplying a universal comparison checklist.

How cannabis-use timing shaped the prospective study

The order of cannabis exposure and vomiting helped researchers define the group they wanted to study. It did not provide a stand-alone diagnostic rule. Keeping that distinction clear also helps separate whole-person care planning from diagnosis. A conversation about adult outpatient admissions addresses substance-use care options, not a research-based determination of what caused recurring vomiting.

In the prospective observational study conducted from September 2021 through August 2022, researchers enrolled 39 adults presenting to emergency departments at two hospitals within one health system. Eligibility required severe cyclic vomiting, abdominal pain, chronic daily cannabis use, a positive urine THC test, and vomiting onset after cannabis initiation. These requirements describe the investigators’ enrollment method, not instructions for diagnosing an individual.

The researchers excluded people whose cyclic vomiting began before cannabis use. They specifically discussed excluding people who had started cannabis in an effort to address preexisting nausea or vomiting. Without that chronology, a study could combine people whose cannabis use preceded their symptoms with people whose symptoms preceded cannabis use. Those are different exposure histories, even if both groups currently report vomiting and cannabis use.

  • Sequence: Did cannabis exposure begin before or after the vomiting pattern? The study selected one sequence to make its research population more specific.
  • Selection: Which other explanations were excluded? Treating physicians helped assess whether an alternative condition could account for symptoms.
  • Interpretation: What can that selected group represent? Findings apply most directly to similarly selected emergency department patients, not every person with nausea or cannabis exposure.

Temporal order is informative because a proposed cause must be considered in relation to when symptoms began. However, an event occurring first does not establish that it caused a later event. The study remained observational, and participant histories depended partly on recall. Its eligibility criteria narrowed uncertainty for research purposes without eliminating the need for clinical judgment or consideration of competing explanations.

What two different CHS study definitions counted

The prospective study counted selected participants, while the national study counted visits that met an administrative definition. That difference changes what their numbers mean. Neither count establishes an individual diagnosis or eligibility for River City Recovery’s outpatient services. Decisions about outpatient program fit and assessment concern a person’s current needs rather than membership in a research category.

The national cross-sectional analysis of emergency department visits from 2016 through 2022 used the Nationwide Emergency Department Sample. Its analytic sample included 188,610,906 unweighted visits, representing approximately 806 million visits after survey weighting. Those totals describe the overall analytic dataset, not the number of CHS visits. The sample included people aged 12 years and older, so it was not exclusively an adult study.

How the two studies approached suspected CHS

Research featureProspective emergency department cohortNational emergency department analysis
Unit counted39 enrolled adult participantsEmergency department visits, including possible repeat visits by the same person
Case definitionSpecified symptoms, cannabis exposure, timing, and physician-informed exclusionsA primary vomiting code plus a secondary cannabis-related code
Information availableParticipant histories, standardized questionnaires, and blood samplingAdministrative diagnoses and visit characteristics
Main boundaryA small, selected group within one health systemA coding proxy that could misclassify or miss cases

No CHS-specific diagnosis code existed during the national study’s 2016–2022 observation period. The investigators therefore used a proxy: a primary diagnosis of cyclical vomiting not associated with migraine, coded R11.15, or unspecified vomiting, coded R11.10, accompanied by a secondary cannabis-specific diagnosis. Including unspecified vomiting means that the research category was broader than clinically confirmed CVS or CHS.

The study also used “cannabis use disorder” as shorthand for a broad administrative category covering cannabis-related use, abuse, dependence, and poisoning diagnoses. The authors stated that this grouping did not precisely match a cannabis use disorder diagnosis under the Diagnostic and Statistical Manual of Mental Disorders. A code-based category should not be read as proof that every included person received that clinical diagnosis.

Nationally, proxy-defined CHS visits increased from approximately 4.4 per 100,000 emergency department visits in 2016 to 22.3 in 2022, with a peak of 33.1 in the second quarter of 2020. These are visit-level rates, not the incidence of new CHS among people who use cannabis. Repeat attendance, changing recognition, underreported cannabis use, and evolving coding practices can affect the pattern.

Both studies tried to reduce ambiguity by excluding alternative explanations, but their methods differed. The prospective study consulted treating physicians about competing conditions. The national analysis excluded specified diagnosis categories, including pregnancy-related vomiting, gastroparesis, migraine-related vomiting, chemotherapy-related nausea, and bulimia. Such exclusions improve research focus without ensuring that every remaining episode has one established cause.

Why hot-water relief and blood findings cannot diagnose CHS

Hot-water relief and cannabis exposure can be relevant observations, but neither settles the diagnosis. Medical questions should remain distinct from planning connected substance-use and health support. The availability of outpatient addiction care does not turn either observation into a diagnostic test or establish a CHS specialty service.

In the prospective cohort, 37 of the 39 enrolled participants reported symptom relief with hot-water bathing. However, the researchers did not require that feature for enrollment because they described the supporting evidence as inconclusive. A commonly reported behavior within a selected group is not the same as a specific test that distinguishes that group from everyone with another explanation for vomiting.

Hot-water relief should therefore not be treated as a home experiment for deciding between CHS and CVS. Nor does a positive cannabis history establish causation. In the prospective study, a positive urine THC result was one enrollment requirement among several. Its role was to help select the research population, not independently confirm the cause of a participant’s vomiting.

The cohort’s cannabis-use and blood-testing results also require careful interpretation. Among participants with available use-frequency data, 84% reported cannabis use more than once daily. Reported median frequency was three sessions on weekdays and four on weekends. Those patterns describe a selected symptomatic emergency department cohort. The study did not establish a frequency or quantity threshold that diagnoses CHS or predicts who will develop it.

Thirty-five participants completed initial and follow-up blood draws. One was excluded from the final cannabinoid analysis because delta-8-THC interfered with measurement, leaving 34. In that analysis, delta-9-THC concentrations did not differ between symptomatic and asymptomatic testing. Two measured THC metabolites were higher at asymptomatic follow-up. These findings did not establish a blood biomarker that could distinguish an individual’s CHS from CVS.

Timing further complicates interpretation. Researchers could not control the interval since participants’ last cannabis use, and that interval relied on self-report. The small sample, single health system, incomplete follow-up, and wide variation in measured concentrations also limit generalization. The findings support further investigation, not a blood-level cutoff or reassurance that a particular result rules illness in or out.

Medical evaluation and outpatient support in Columbus, GA

Recurring or concerning vomiting warrants clinical assessment rather than a conclusion based on symptom comparisons. Separately, adults concerned about substance use can explore River City Recovery’s outpatient addiction treatment in Columbus, GA or contact admissions about available adult outpatient care. Medical evaluation of vomiting and assessment of substance-use treatment needs serve different purposes.

For severe symptoms or immediate danger, call 911 rather than waiting for a routine outpatient response. A non-emergency admissions conversation is not a substitute for urgent medical attention. The research does not provide a safe way for an individual to decide that recurring vomiting is cannabis-related, unrelated to cannabis, or explained by CVS without appropriate evaluation.

River City Recovery’s verified adult outpatient options include PHP, IOP, Evening IOP, and outpatient therapy. Available support can include individual therapy, family support, case management, and care coordination, depending on assessed needs. These are outpatient substance-use and mental health services. Their availability does not establish emergency vomiting evaluation, gastroenterology specialty care, or diagnosis or treatment of CHS or CVS.

  • Medical assessment: Addresses recurring vomiting, possible competing causes, and the appropriate medical setting.
  • Substance-use assessment: Considers concerns about use, its effects on daily life, and whether outpatient addiction care may fit.
  • Care coordination: Helps connect relevant needs and services without assuming that every concern can be addressed in one program or building.

The whole-person planning approach is relevant because medical and mental health needs should not disappear when substance use is discussed. Coordination can recognize that a person may need outside medical care alongside addiction support. It does not imply a particular referral partnership, an on-site specialty, or a predetermined explanation for symptoms.

An adult or loved one can begin a non-emergency admissions conversation without selecting a program or diagnosing the problem first. Admissions can explain available services and possible assessment steps. Calling does not guarantee admission or a particular level of care. The goal is to understand current substance-use concerns while keeping unresolved medical questions connected to appropriate professional care.

Frequently asked questions

Why can CHS and cyclic vomiting symptoms overlap?

CHS and CVS can involve recurring vomiting, and nausea or abdominal pain does not establish the cause. The prospective study described difficulty distinguishing suspected CHS from CVS in people with chronic cannabis use during an emergency visit. Neither study established a symptom checklist that reliably separates the conditions for an individual.

Why does the timing of cannabis use matter in research?

The prospective study required vomiting to begin after cannabis initiation and excluded people whose vomiting began first. That helped researchers avoid combining different exposure histories, including people who started cannabis because of existing symptoms. However, a sequence in time does not by itself prove causation, and enrollment requirements are not universal diagnostic rules.

How did the studies define and count suspected CHS?

The prospective study enrolled 39 adults using specified symptoms, cannabis exposure, timing, and physician-informed exclusions. The national study used primary vomiting codes plus secondary cannabis-related codes as a CHS proxy because no dedicated code existed during 2016–2022. It counted emergency department visits, not unique people, and included ages 12 years and older.

Can hot-water relief or cannabis history determine the diagnosis?

No. Hot-water relief was common in the selected prospective cohort, but it was not required for enrollment because the researchers described the evidence as inconclusive. Cannabis history and a positive THC test also did not independently establish the cause of vomiting. These observations should not become home tests for choosing between CHS and CVS.

Why can study patterns not diagnose an individual?

Research findings depend on who was included, how conditions were defined, and what information was available. A small selected cohort and a national coding analysis have different limitations. Neither supplies an individual diagnosis, a reliable cannabis-exposure threshold, or a predictive blood marker. Recurring or concerning vomiting requires appropriate clinical assessment rather than comparison with study averages.

Explore related information from River City Recovery

Contact River City Recovery